OTCMKTS:ASPCF

Acerus Pharmaceuticals - ASPCF Stock Forecast, Price & News

$0.85

0.00 (0.00%)

(As of 12/2/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.85
▼
$0.85
50-Day Range: $0.85
▼
$1.85
52-Week Range: $0.85
▼
$8.16

Volume: N/A
Average Volume: 25 shs
Market Capitalization: $6.55 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Acerus Pharmaceuticals (OTCMKTS:ASPCF) Stock

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Receive ASPCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ASPCF Stock News Headlines

November 15, 2022 | finance.yahoo.com

Acerus Reports Third Quarter 2022 Financial Results

October 3, 2022 | finance.yahoo.com

Acerus Announces Amendment to Promissory Note Due to Former Serenity Shareholders

September 21, 2022 | marketwatch.com

Acerus Pharmaceuticals to Initiate Strategic Review of Operations

September 21, 2022 | finance.yahoo.com

Acerus Announces Initiation of Strategic Review

August 23, 2022 | seekingalpha.com

Acerus Pharmaceuticals CFO resigns effective November 20, 2022

August 14, 2022 | seekingalpha.com

Acerus Pharmaceuticals Corporation (ASPCF) CEO Edward Gudaitis on Q2 2022 Results - Earnings Call Transcript

August 5, 2022 | finance.yahoo.com

Acerus Announces Amendments to Loan Facility and Promissory Note Due to Former Serenity Shareholders

June 27, 2022 | finance.yahoo.com

Acerus Announces Voting Results for the 2022 Annual Meeting

June 24, 2022 | seekingalpha.com

Acerus Pharmaceuticals increases loan facility to $37.94M

May 11, 2022 | seekingalpha.com

Acerus Pharmaceuticals GAAP EPS of $0.00, revenue of $0.78M

May 5, 2022 | finance.yahoo.com

Acerus To Report Q1-2022 Financial Results And Host Investor Call

April 26, 2022 | finance.yahoo.com

Acerus Announces Completion of Share Consolidation

April 19, 2022 | finance.yahoo.com

Acerus Announces Share Consolidation

February 28, 2022 | seekingalpha.com

Acerus to acquire Florida-based Serenity in cash/stock deal

February 28, 2022 | finance.yahoo.com

Acerus Announces Definitive Agreement to Acquire Serenity LLC and the Global Rights to Noctiva™

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ASPCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ASPCF Company Calendar

Last Earnings: 11/14/2022
Today: 12/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:ASPCF
CUSIP: N/A
CIK: N/A
Web: www.aceruspharma.com
Phone: (416) 679-0771
Fax: 905-569-1809
Employees: 14
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($3.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-33,820,000.00
Net Margins: -924.33%
Pretax Margin: -1,008.97%
Return on Equity: N/A
Return on Assets: -81.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.37
Quick Ratio: 0.16

Sales & Book Value

Annual Sales: $2.12 million
Price / Sales: 3.09
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($3.38) per share
Price / Book: -0.25

Miscellaneous

Outstanding Shares: 7,710,000
Free Float: N/A
Market Cap: $6.55 million
Optionable: Not Optionable
Beta: 0.59

Key Executives

Mr. Edward Gudaitis
Pres, CEO & Director

Mr. Gavin Damstra
Sr. VP of International Commercial

Dr. Christopher Sorli F.A.C.E.
M.D., Ph.D., Chief Medical Officer

Mr. Kevin Thomas Hickey
Sr. VP of US Commercial

Mr. Naveed Manzoor
Interim Chief Financial Officer

Mr. Chris Witty
Investor Relations

Mr. Philippe Savard
Sr. VP, Gen. Counsel & Corp. Sec.

Mr. Hubert Tomasz Czerwinski
Pres of Acerus Pharmaceuticals SRL

Key Competitors

View All Competitors

ASPCF Stock - Frequently Asked Questions

How have ASPCF shares performed in 2022?: Acerus Pharmaceuticals' stock was trading at $4.06 on January 1st, 2022. Since then, ASPCF stock has decreased by 79.1% and is now trading at $0.85.
View the best growth stocks for 2022 here.
Are investors shorting Acerus Pharmaceuticals?: Acerus Pharmaceuticals saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 1,400 shares, an increase of 100.0% from the October 15th total of 700 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is presently 14.0 days.
View Acerus Pharmaceuticals' Short Interest.
How were Acerus Pharmaceuticals' earnings last quarter?: Acerus Pharmaceuticals Co. (OTCMKTS:ASPCF) issued its earnings results on Monday, November, 14th. The company reported ($0.54) earnings per share (EPS) for the quarter. The company had revenue of $0.77 million for the quarter.
When did Acerus Pharmaceuticals' stock split?: Acerus Pharmaceuticals shares reverse split on the morning of Friday, April 29th 2022. The 1-200 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What is Acerus Pharmaceuticals' stock symbol?: Acerus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ASPCF."
How do I buy shares of Acerus Pharmaceuticals?: Shares of ASPCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Acerus Pharmaceuticals' stock price today?: One share of ASPCF stock can currently be purchased for approximately $0.85.
How much money does Acerus Pharmaceuticals make?: Acerus Pharmaceuticals (OTCMKTS:ASPCF) has a market capitalization of $6.55 million and generates $2.12 million in revenue each year. The company earns $-33,820,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis.
How can I contact Acerus Pharmaceuticals?: Acerus Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The official website for the company is www.aceruspharma.com. The company can be reached via phone at (416) 679-0771, via email at ir@aceruspharma.com, or via fax at 905-569-1809.

This page (OTCMKTS:ASPCF) was last updated on 12/3/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial